<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01571297</url>
  </required_header>
  <id_info>
    <org_study_id>RM-131-004</org_study_id>
    <nct_id>NCT01571297</nct_id>
  </id_info>
  <brief_title>Phase 2 Study to Evaluate Safety &amp; Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Motus Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Motus Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of RM-131 on gastric emptying,&#xD;
      gastroparesis symptoms, and the safety and tolerability of RM-131 compared to placebo in&#xD;
      patients with Type 1 and Type 2 diabetes mellitus and gastroparesis. The study is designed to&#xD;
      evaluate the efficacy and safety of multiple dose regimens of RM-131. Study drug (RM-131 and&#xD;
      placebo) will be administered subcutaneously in a blinded fashion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of RM-131 on gastric emptying time</measure>
    <time_frame>Screening and Day 28</time_frame>
    <description>Change from baseline in gastric half-emptying time (t½)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of RM-131 on symptoms of gastroparesis</measure>
    <time_frame>Baseline, daily for 28 days, and Day 35</time_frame>
    <description>Longitudinal change from baseline over time in daily symptom scores from a self administered daily symptom diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of RM-131</measure>
    <time_frame>From Screening through Day 35</time_frame>
    <description>Assessment of adverse events and clinical laboratory evaluations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">204</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Diabetes Mellitus Complications</condition>
  <condition>Gastroparesis</condition>
  <arm_group>
    <arm_group_label>RM-131</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RM-131</intervention_name>
    <description>Double blind RM-131 will be studied with various doses and regimens from 10 to 100 μg for 35 days.</description>
    <arm_group_label>RM-131</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo given subcutaneously for 35 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to provide written informed consent prior to any study procedures and be willing&#xD;
             and able to comply with study procedures.&#xD;
&#xD;
          -  Type 1 or Type 2 diabetes mellitus with HbA1c ≤11% at screening.&#xD;
&#xD;
          -  Diabetic gastroparesis defined as at least 3 months history of symptoms suggestive of&#xD;
             gastroparesis on an ongoing basis.&#xD;
&#xD;
          -  Average Gastroparesis Cardinal Symptom Index Daily Diary (GCSI-DD) &gt; 2.6 during Visit&#xD;
             2.&#xD;
&#xD;
          -  History of nausea and/or vomiting/emesis at least once a week during the 2 weeks prior&#xD;
             to Visit 1.&#xD;
&#xD;
          -  Delayed gastric emptying confirmed at screening by abnormal gastric emptying breath&#xD;
             test (GEBT), defined as half-emptying time (t½) &gt; 79 minutes.&#xD;
&#xD;
          -  Stable concomitant medications defined as no changes in regimen for at least 2 weeks&#xD;
             prior to Visit 2.&#xD;
&#xD;
          -  No use of metoclopramide, erythromycin or anti-emetics for at least 2 weeks prior to&#xD;
             Visit 2.&#xD;
&#xD;
          -  Body mass index &gt; 18 kg/m2.&#xD;
&#xD;
          -  Female patients must have negative serum or urine pregnancy tests and must not be&#xD;
             lactating. For females able to bear children, a hormonal (i.e., oral, implantable, or&#xD;
             injectable) and single-barrier method, or a double-barrier method of birth control&#xD;
             must be used throughout the study. Female patients unable to bear children must have&#xD;
             this documented in the electronic case report form (eCRF) (i.e., tubal ligation,&#xD;
             hysterectomy, or post-menopausal [defined as a minimum of one year since the last&#xD;
             menstrual period]). Post-menopausal status will be confirmed by FSH.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently receiving parenteral feeding; presence of a nasogastric or other enteral&#xD;
             tube for feeding or decompression.&#xD;
&#xD;
          -  History of gastric surgery such as fundoplication, gastrectomy, gastric pacemaker&#xD;
             placement, vagotomy, bariatric procedure.&#xD;
&#xD;
          -  History of pyloric injection of botulinum toxin within 6 months of screening.&#xD;
&#xD;
          -  Persistent daily vomiting.&#xD;
&#xD;
          -  Patients with clinical suspicion of upper gastrointestinal obstruction must have been&#xD;
             evaluated per standard of care, and obstruction ruled out before screening.&#xD;
&#xD;
          -  Currently taking opiates.&#xD;
&#xD;
          -  Currently taking GLP-1 and amylin analogs.&#xD;
&#xD;
          -  Allergic or intolerant of egg, wheat, milk or algae, as these are components of the&#xD;
             GEBT study meal.&#xD;
&#xD;
          -  History of anorexia nervosa, binge-eating or bulimia within 5 years.&#xD;
&#xD;
          -  ALT or AST &gt; 2 X upper limit of normal during screening.&#xD;
&#xD;
          -  History of intestinal malabsorption or pancreatic exocrine disease.&#xD;
&#xD;
          -  Requires hemodialysis or has end-stage renal disease.&#xD;
&#xD;
          -  History of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  Clinically significant neurologic or psychiatric disorders which are likely to impact&#xD;
             compliance with protocol requirements.&#xD;
&#xD;
          -  Poor venous access or inability to tolerate venipuncture.&#xD;
&#xD;
          -  Participation in a clinical study within the 30 days prior to dosing in the present&#xD;
             study.&#xD;
&#xD;
          -  Any other reason, which in the opinion of the Investigator, including renal, hepatic&#xD;
             or cardiopulmonary disease, or significant acute ECG abnormalities that would confound&#xD;
             proper interpretation of the study or expose a patient to unacceptable risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Development Officer</last_name>
    <role>Study Director</role>
    <affiliation>Rhythm Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Concord</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>April 2, 2012</study_first_submitted>
  <study_first_submitted_qc>April 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2012</study_first_posted>
  <disposition_first_submitted>November 6, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>November 6, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 19, 2014</disposition_first_posted>
  <last_update_submitted>September 21, 2016</last_update_submitted>
  <last_update_submitted_qc>September 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Delayed Gastric Emptying</keyword>
  <keyword>Gastroparesis</keyword>
  <keyword>Gastrointestinal Motility Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

